Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, Liu Z, Ozyilkan O, Igor B, Chen J, Oleksandr K, Chen Z, Zhang H, Fu Z, Dong Q, Song S, Yu JC, Zhang L. Chen L, et al. Among authors: cil t. Cancer Med. 2023 Nov;12(22):20847-20863. doi: 10.1002/cam4.6664. Epub 2023 Nov 7. Cancer Med. 2023. PMID: 37935428 Free PMC article. Clinical Trial.
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Vokes EE, et al. Among authors: cil t. J Thorac Oncol. 2024 Feb;19(2):285-296. doi: 10.1016/j.jtho.2023.09.1452. Epub 2023 Oct 4. J Thorac Oncol. 2024. PMID: 37797733 Free article. Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Among authors: cil t. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Brigatinib-associated autoimmune hepatitis: A case report.
Buyuksimsek M, Ogul A, Yetisir AE, Duman BB, Tohumcuoglu M, Cil T, Koseci T, Kidi MM, Sumbul HE. Buyuksimsek M, et al. Among authors: cil t. J Oncol Pharm Pract. 2023 Apr 18:10781552231171322. doi: 10.1177/10781552231171322. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37073439
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. Among authors: cil t. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.
Ozbay MF, Harputluoglu H, Karaca M, Tekin O, Şendur MAN, Kaplan MA, Sahin B, Geredeli C, Teker F, Tural D, Saglam S, Çil T, Bilici A, Erol C, Kalkan Z, Bayram E, Selvi O, Gültürk İ, Göksu SS, Tatlı AM. Ozbay MF, et al. Among authors: cil t. Cancers (Basel). 2024 Nov 20;16(22):3880. doi: 10.3390/cancers16223880. Cancers (Basel). 2024. PMID: 39594835 Free PMC article.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
144 results